Fig. 8.
Prevention of EBV-specific CD8+ cell loss by CD28 costimulation after a 12-day culture.
Frequency of EBV-reactive cells from 4 donors, as assessed by HLA-A2/GLC peptide tetramer staining or by ELISPOT assay (after stimulation by an autologous B-EBV cell line), in PBMCs and GMCs generated after an initial PBMC activation by CD3/IL-2 or CD3/CD28/IL-2. Data are representative of 3 tetramer staining experiments and 4 ELISPOT experiments.